In the past week, MNKD stock has gone up by 7.38%, with a monthly gain of 26.20% and a quarterly surge of 36.46%. The volatility ratio for the week is 4.32%, and the volatility levels for the last 30 days are 4.91% for Mannkind Corp . The simple moving average for the past 20 days is 13.00% for MNKD’s stock, with a 44.55% simple moving average for the past 200 days.
Is It Worth Investing in Mannkind Corp (NASDAQ: MNKD) Right Now?
Mannkind Corp (NASDAQ: MNKD) has a higher price-to-earnings ratio of 181.44x compared to its average ratio, The 36-month beta value for MNKD is at 1.31. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for MNKD is 266.41M, and currently, shorts hold a 15.46% of that float. The average trading volume for MNKD on September 17, 2024 was 2.72M shares.
MNKD) stock’s latest price update
The stock price of Mannkind Corp (NASDAQ: MNKD) has jumped by 4.47 compared to previous close of 6.27. Despite this, the company has seen a gain of 7.38% in its stock price over the last five trading days. globenewswire.com reported 2024-09-10 that DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that Chief Financial Officer Chris Prentiss and Dr. Wasim Fares Therapeutic Area Head, Orphan Lung Diseases, will share updates during a fireside chat at the 2024 Cantor Fitzgerald Global Healthcare Conference in New York.
Analysts’ Opinion of MNKD
Many brokerage firms have already submitted their reports for MNKD stocks, with Leerink Partners repeating the rating for MNKD by listing it as a “Outperform.” The predicted price for MNKD in the upcoming period, according to Leerink Partners is $8 based on the research report published on September 09, 2024 of the current year 2024.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see MNKD reach a price target of $8. The rating they have provided for MNKD stocks is “Buy” according to the report published on June 13th, 2024.
Wedbush gave a rating of “Outperform” to MNKD, setting the target price at $10 in the report published on October 10th of the previous year.
MNKD Trading at 16.37% from the 50-Day Moving Average
After a stumble in the market that brought MNKD to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 1.71% of gains for the given period.
Volatility was left at 4.91%, however, over the last 30 days, the volatility rate increased by 4.32%, as shares surge +27.43% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +27.68% upper at present.
During the last 5 trading sessions, MNKD rose by +7.38%, which changed the moving average for the period of 200-days by +87.14% in comparison to the 20-day moving average, which settled at $5.87. In addition, Mannkind Corp saw 79.95% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MNKD starting from Tross Stuart A, who sale 25,000 shares at the price of $6.26 back on Sep 03 ’24. After this action, Tross Stuart A now owns 1,022,191 shares of Mannkind Corp, valued at $156,500 using the latest closing price.
STUART A TROSS, the Officer of Mannkind Corp, proposed sale 25,000 shares at $6.26 during a trade that took place back on Sep 03 ’24, which means that STUART A TROSS is holding shares at $156,380 based on the most recent closing price.
Stock Fundamentals for MNKD
Current profitability levels for the company are sitting at:
- 0.19 for the present operating margin
- 0.71 for the gross margin
The net margin for Mannkind Corp stands at 0.05. The total capital return value is set at 0.13.
Based on Mannkind Corp (MNKD), the company’s capital structure generated 16.16 points at debt to capital in total, while cash flow to debt ratio is standing at 0.17. The debt to equity ratio resting at -1.07. The interest coverage ratio of the stock is 1.44.
Currently, EBITDA for the company is 16.39 million with net debt to EBITDA at 4.5. When we switch over and look at the enterprise to sales, we see a ratio of 8.22. The receivables turnover for the company is 10.29for trailing twelve months and the total asset turnover is 0.56. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.07.
Conclusion
In conclusion, Mannkind Corp (MNKD) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
